Halozyme Therapeutics (NASDAQ:HALO) versus GW Pharmaceuticals PLC- (GWPH) Head to Head Review

GW Pharmaceuticals PLC- (NASDAQ: GWPH) and Halozyme Therapeutics (NASDAQ:HALO) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Earnings & Valuation

This table compares GW Pharmaceuticals PLC- and Halozyme Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GW Pharmaceuticals PLC- $11.00 million 332.71 -$166.90 million ($7.05) -18.69
Halozyme Therapeutics $146.69 million 19.16 -$103.02 million ($0.68) -29.03

Halozyme Therapeutics has higher revenue and earnings than GW Pharmaceuticals PLC-. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than GW Pharmaceuticals PLC-, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for GW Pharmaceuticals PLC- and Halozyme Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GW Pharmaceuticals PLC- 0 1 7 0 2.88
Halozyme Therapeutics 1 2 3 0 2.33

GW Pharmaceuticals PLC- currently has a consensus price target of $152.50, indicating a potential upside of 15.71%. Halozyme Therapeutics has a consensus price target of $18.67, indicating a potential downside of 5.44%. Given GW Pharmaceuticals PLC-‘s stronger consensus rating and higher probable upside, analysts plainly believe GW Pharmaceuticals PLC- is more favorable than Halozyme Therapeutics.

Insider and Institutional Ownership

74.6% of GW Pharmaceuticals PLC- shares are owned by institutional investors. Comparatively, 84.5% of Halozyme Therapeutics shares are owned by institutional investors. 16.8% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares GW Pharmaceuticals PLC- and Halozyme Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
GW Pharmaceuticals PLC- -1,607.85% -40.42% -34.97%
Halozyme Therapeutics -53.17% -892.57% -29.67%

Volatility & Risk

GW Pharmaceuticals PLC- has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company’s commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant. The Company’s development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply